Role of 18F-FDG PET/CT in detection of hematogenous metastases of advanced differentiated thyroid carcinoma: a systematic review and meta-analysis

Quartuccio, Natale; Rubello, Domenico

doi:10.20517/2394-4722.2020.118

Cited by 3 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beta-emitting radionuclides encompass Phosphorus-32 ( 32 P), Strontium-89 ( 89 Sr), Renium-186 and -188 ( 186 Re, 188 Re), Samarium-153 ( 153 Sm), Selenium-117m ( 117m Sn), and Lutetium-177 ( 177 Lu) ( 29 ). Apart from these, a special mention is needed for 131 I, whose use against BMs has been limited in patients with thyroid cancer ( 30 ). Conversely, alpha-emitting therapy currently relies primarily on the clinical use of Radium-223 ( 223 Ra).…”

Section: Resultsmentioning

confidence: 99%

A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors

et al. 2022

Self Cite

View full text Add to dashboard Cite

Context: Bone metastasis (BM) is a frequent complication of cancer, representing the third most common site of secondary spread in solid cancers behind the lung and liver. Bone metastasis is found in up to 90% of prostate and breast cancer patients. They can cause significant complications, such as pathological fractures and paralysis of the spine, which decrease daily functioning and quality of life (QoL) and worsen prognosis. The growing life expectancy of cancer patients due to improvements in systemic therapies may further increase BM's eventuality and clinical burden in cancer patients. Evidence Acquisition: Four physicians from five different specialties were interviewed and resumed the most relevant literature of the last 20 years focusing on pain treatment in BM patients. Results: Treatment for BM ideally involves various types of specialists and assessments. The disease status and patient background should be considered, requiring holistic care and expertise from various medical specialties. Conclusions: Interventional, nuclear medicine, radiotherapy, and mini-invasive techniques can be safe and effective for relieving pain and modifying health-related QoL in BM patients.

show abstract

Section: Resultsmentioning

confidence: 99%

A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The difference in terms of DR of these two instrumental examinations might underlie the variable diagnostic accuracy of [ 18 F]FDG PET in DTC, which is affected by several different clinical and histological features ( 40 – 42 ); however, since none of the included studies assessed the differences in diagnostic accuracy of both examinations based on histologic variants and clinical features; it is not feasible to validate this hypothesis. In this setting, it is noteworthy that [ 18 F]FDG has a valuable diagnostic performance in DTC patients with hematogenous metastases, as stated in a recent meta-analysis of literature ( 43 ); unfortunately, it is currently not feasible to make an indirect comparison of these two imaging techniques since the data gathered in this systematic review does not allow to pool the diagnostic accuracies reported in the included studies. More studies are needed in this setting to assess which patients might benefit from FAP-targeted imaging rather than [ 18 F]FDG PET.…”

Section: Discussionmentioning

confidence: 97%

Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review

Rizzo,

Albano,

Dondi

et al. 2024

Front. Med.

View full text Add to dashboard Cite

BackgroundSeveral recent studies have proposed the possible application of positron emission tomography/computed tomography (PET/CT) administering radiolabelled fibroblast-activation protein (FAP) inhibitors for various forms of thyroid cancer (TC), including differentiated TC (DTC), and medullary TC (MTC).MethodsThe authors conducted an extensive literature search of original studies examining the effectiveness of FAP-guided PET/CT in patients with TC. The papers included were original publications exploring the use of FAP-targeted molecular imaging in restaging metastatic DTC and MTC patients.ResultsA total of 6 studies concerning the diagnostic yield of FAP-targeted PET/CT in TC (274 patients, of which 247 DTC and 27 MTC) were included in this systematic review. The included articles reported high values of FAP-targeted PET/CT detection rates in TC, ranging from 81 to 100% in different anatomical sites and overall superior to the comparative imaging method.ConclusionAlthough there are promising results, the existing literature on the diagnostic accuracy of FAP-guided PET in this context is still quite limited. To thoroughly evaluate its potential significance in TC patients, it is needed to conduct prospective randomized multicentric trials.

show abstract

“…Anaplastic thyroid cancer (ATC) is still a rapidly deadly tumor without any established therapy. Lee and Cheng [5] present elegant studies of transcriptional pathways to explain transcriptional addiction that makes this tumor so difficult to treat effectively. They propose the use of small molecule inhibitors to target the transcriptional regulators in ATC.…”

Section: Davidson and Carrmentioning

confidence: 99%

New developments in management of metastatic thyroid cancer

Hershman¹

2022

JCMT

View full text Add to dashboard Cite

Role of 18F-FDG PET/CT in detection of hematogenous metastases of advanced differentiated thyroid carcinoma: a systematic review and meta-analysis

Abstract: How to cite this article: Quartuccio N, Rubello D. Role of 18 F-FDG PET/CT in detection of hematogenous metastases of advanced differentiated thyroid carcinoma: a systematic review and meta-analysis.

Cited by 3 publications

References 33 publications

A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors

A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors

Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review

New developments in management of metastatic thyroid cancer

Contact Info

Product

Resources

About